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Abstract
Background: Each year approximately 6,000 new cases of head and neck cancer are registered in Poland. Human
papillomavirus (HPV) and Epstein-Barr virus (EBV) have been associated with tumour formation. Cytokines have been
shown to play an important role both in inflammation and carcinogenesis and they can be detected in saliva and
serum with ELISA assays. Salivary biomarkers may be used as markers of early cancer detection.
The aim of this study was the analysis of the serum and salivary levels of IL-10, TNF-α, TGF-β and VEGF in patients
with oropharyngeal cancer and in healthy individuals. The level of these biomarkers was also analyzed in HPV- and
EBV-related cases.
Methods: The study involved 78 patients with histopathologically confirmed oropharyngeal squamous cell
carcinoma and 40 healthy controls. Serum and salivary levels of IL-10, TNF-α, TGF-β and VEGF were analyzed both
in patients and in healthy individuals by ELISA method using Diaclone SAS commercially available kits (France). EBV
DNA was detected by the nested PCR for amplification of EBNA-2. HPV detection and genotyping was performed
using the INNO-LiPA HPV Genotyping Extraassay (Innogenetics N. V, Gent, Belgium). The obtained results were
subjected to statistical analysis using Mann–Whitney and Kruskal Wallis tests. Test values of p < 0.05 were
considered statistically significant.
Results: The level of tested cytokines was higher in patients than in controls both in serum (IL-10: 2.3 pg/ml vs 1.
65 pg/ml, p = 0.0003; TGF-β: 11.3 ng/ml vs 7.8 ng/ml, p = 0.0005; VEGF: 614 pg/ml vs 210 pg/ml, p = 0.0004; TNF-α:
15.0 ng/ml vs 12.90 ng/ml, p = 0.1397) as well as in saliva (IL-10: 5.9 pg/ml vs 2.5 pg/ml, p = 0.00002; TGF-β: 24.
1 ng/ml vs 14.8 ng/ml, p = 0.00002; VEGF: 4321 pg/ml vs 280 pg/ml, p = 0.0000; TNF-α: 23.1 ng/ml vs 11.3 ng/ml,
p = 0.00002).
EBV DNA was detected in 51.3 % of patients and 20 % of controls, HPV DNA was present in 30.8 % of patients
and 2,5 % of controls.
The level of IL-10 was statistically higher in patients infected with EBV, HPV and co-infected with EBV/HPV. The
level of TNF-α was significantly higher in patients infected with EBV, while TGF-β in patients with HPV infection
and EBV/HPV co-infection.
Conclusion: Detection of salivary cytokines may be very helpful in early diagnosis, treatment and prognosis of OSCC.
Keywords: Cytokines, Inflammation, Oropharyngeal cancer, HPV, EBV
* Correspondence: malgorzata.strycharz-dudziak@umlub.pl
2Department and Chair of Conservative Dentistry with Endodontics, Medical
University of Lublin, Lublin, Poland
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Polz-Dacewicz et al. Infectious Agents and Cancer  (2016) 11:45 
DOI 10.1186/s13027-016-0093-6
Background
Oral Squamous Cell Carcinoma (OSCC) as the most fre-
quently diagnosed cancer in the head and neck region is
a very important world-wide health problem [1]. About
90 % of all malignant tumours localised in the oral cavity
and oropharynx are squamous cell carcinomas (SCC).
Mortality for oral cancer is high because the early phase
of the disease is often asymptomatic and most patients
seek care with the late-stage symptoms [2]. Tobacco and
alcohol are well-established risk factors for OSCC. Onco-
genic viruses have also been involved in OSCC develop-
ment [1, 3–8]. The International Agency for Research on
Cancer (IARC) concluded that there is an evidence for a
role of human papillomavirus (HPV), in particular HPV16,
in the oropharyngeal cancer [9, 10]. A number of studies
also suggest the role of Epstein-Barr virus (EBV) in the de-
velopment of cancer in this region [11–14]. Many studies
indicate that genetic mutations caused by oncogenic viruses
lead to a different rates of tumour disease development.
This effect is due to the varying levels of cytokines and
other growth factors. These disorders lead to a faster (or
slower) tumour growth as well as metastasis formation [15].
It has been shown that inflammation plays a key role in
different stages of carcinogenesis. Cytokines are a group of
host immune products involved in inflammation, immunity
and defence against HPV infection, and modulation of HPV
clearance plays an important role in oncogenesis [16]. Of
particular interest has been the use of the salivary cytokine
concentration as a marker of cell proliferation. The most
studied cytokines include interleukin 10 (IL-10), tumour
necrosis factor-alpha (TNF-α), vascular endothelial growth
factor (VEGF) and tumour growth factor-beta (TGF-β).
These salivary biomarkers were demonstrated to be in-
creased in patients with oral cancer and several of them are
still candidates for future clinical use [16–18]. Saliva is a
body fluid very useful for the early diagnosis, monitoring
and treatment of diseases [18]. Therefore, the aim of this
study was to analyze the serum and salivary levels of IL-10,
TNF-α, TGF-β and VEGF in patients with oropharyngeal
cancer compared to healthy individuals. We also analyzed
the level of these biomarkers in HPV- and EBV-related
cases.
This research was approved by the Ethics Commit-




The study was conducted among 78 patients with diag-
nosed and histopathologically confirmed OSCC hos-
pitalized at the Otolaryngology Division of the Hospital
in Radom, Poland. The patients had neither previous
radiotherapy nor chemotherapy. The results were com-
pared to 40 healthy controls. The control group
involved persons hospitalized at the Otolaryngology
Division due to diseases other than cancer. There were
no statistically significant differences between the pa-
tients and the control group (age, sex, tobacco and al-
cohol consumption) (Table 1). Male patients dominated
in the examined group (91.03 %). The patients’ ages
ranged from 40 to 79 years. Most of the patients were
aged 50–69 years (43.6 %), 15.4 % were under 50 years
of age. Most studied individuals (64.1 %) lived in urban
areas. A total of 79.5 % of the studied patients reported
smoking, while 43.6 % pointed to alcohol abuse.
DNA extraction from fresh frozen tumour tissue
Fragments of fresh frozen tumour tissue (20 mg) both from
the patients with OSCC and from the control subjects were
cut and homogenized in a manual homogenizer Omni TH/
Omni International/ Kennesewa/ Georgia /USA. DNA was
extracted using a protocol as described in the DNeasy
Tissue Kit Handbook (Qiagen GmBH, Hilden, Germany).
Purified DNA was quantified by spectrophotometer (Epoch
Microplate Spectrophotometer, BioTek Instruments Inc.,
Vinooski, Vermont, USA). The isolates were kept at
−20 °C until the test was conducted. To verify the quality
of the obtained DNA (presence of inhibitors of Polymer-
ase Chain Reaction), assay of β-globin was performed.
Serum collection
Venous blood samples from patients and control
group were centrifuged at 1500 rpm for 15 min at
Table 1 Demographic and virological characteristics of patients
and controls
Patients Controls P value
N % N %
Sex female 7 8.97 5 7.5 >0.05
male 71 91.03 35 92.5
Age 40–49 12 15.4 7 17.5 >0.05
50–69 34 43.6 19 47.5
70 + 32 41.0 14 35.0
Place of residence urban 50 64.1 26 65.0 >0.05
rural 28 35.9 14 35.0
Smoking yes 62 79.5 32 80.0 >0.05
no 16 20.5 8 20.0
Alcohol yes 34 43.6 20 50.0 >0.05
no 44 56.4 20 50.0
EBV DNA positive 40 51.3 8 20.0 <0.001*
negative 37 47.4 32 80.0
HPV DNA positive 24 30.8 1 2.5 <0.001*
negative 54 69.2 39 97.5
*statistically significant
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room temperature and the serum was collected and
frozen at −80 °C until analysis.
Saliva collection
About 5 ml of unstimulated whole saliva was collected.
The saliva samples were centrifuged at 1500 rpm at
room temperature for 10 min and diluted (1:1) in PBS
and frozen at -80 °C until analysis.
Detection of viruses
EBV DNA detection: All polymerase chain reaction (PCR)
reactions were carried out in the final volume of 25 μl using
HotStartTaq DNA Polymerase (Qiagen, Germany). Concen-
trations of PCR reaction components were prepared as
follows: 2.0 mM MgCl2, 0.2 mM dNTPs, 0.5 μM each
forward and reverse primers and 0.5 U of HotStart
Taq polymerase. During each run the samples were
tested together with one negative (nuclease-free water)
and one positive control (EBV-positive cell line, Namalwa,
ATCC-CRL-1432).
Amplification of EBNA-2 gene: The nested PCR was
carried out for amplification of Epstein-Barr nuclear
antigen 2 (EBNA-2). The sequence of primers used for
PCR was as follows: outer pair 5’ – TTT CAC CAA
TAC ATG ACC C – 3’, 5’ – TGG CAA AGT GCT GAG
AGC AA – 3’ and inner pair 5’ – CAA TAC ATG AAC
CRG AGT CC – 3’, 5’ – AAG TGC TGA GAG CAA
GGC MC – 3’. 2 μl of extracted DNA was subjected to
the PCR mixture with the concentration as described
above. The first-round amplification consisted of activa-
tion of polymerase 95 °C for 15 min, 35 cycles of 94 °C
for 1 min, 55 °C for 1 min, 72 °C for 2 min and the final
extension at 72 °C for 5 min. The second-round amplifi-
cation was performed with 1 μl of first round PCR prod-
uct in 30 cycles with an annealing temperature at 60 °C.
The amplicons 368 bp, 473 bp in length (depending on
the EBV type EBV-1 and EBV-2, respectively) were sepa-
rated on 2 % agarose gel and purified using Gel-Out kit
(A&A Biotechnology, Poland) for further analysis. Puri-
fied PCR products were sent to Genomed Warsaw com-
pany for sequencing.
HPV DNA detection: HPV detection and genotyping
was performed using the INNO-LiPA HPV Genotyping
Extraassay (Innogenetics N. V, Gent, Belgium; no cat.
81063) according to the manufacturer’s protocol. The kit
is based on the amplification of a 65 bp fragment from the
L1 region of the HPV genome. PCR products are subse-
quently typed with the reverse hybridization assay. The
assay covers all currently known high-risk HPV genotypes
and probable high-risk HPV genotypes (16, 18, 26, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as well
as a number of low-risk HPV genotypes (6, 11, 40, 43,
44, 54, 70) and some additional types (69, 71, 74).
Measuring of cytokines level
The levels of IL-10, TNF-α, TGF-β and VEGF were
established in the saliva and sera of patients and healthy
subjects by ELISA (enzyme-linked immunosorbent assay)
using commercially available kits Diaclone SAS, France.
The cytokine level of each serum sample was tested three
times and the results are the means of these. The level of
tested cytokines are expressed in pg/ml or ng/ml. The
minimum detectable dose of IL-10 is less than 0.98 pg/ml
(IL-10 HS ELISA kit) cat. no. 850.880.096; TNF-α – less
than 8 pg/ml cat. no 950.090.096; TGF-β – 8.6 pg/ml
cat. no. 650.010.096 and VEGF – 7.9 pg/ml cat. no.
650.080.096.
Statistical analysis
To examine differences between the patients and controls
in the distributions of demographic variables, smoking
and drinking status, HPV and EBV status Pearson’s chi-
square test was used. The Mann-Whitney test was used to
compare the concentration of cytokines in patients and
controls. The Kruksal-Wallis test was used to determine
the association of the concentration of studied cytokines
with such variables as smoking, alcohol abuse, histological
grade (G) of the tumour, tumour (T) and node (N) stage
according to TNM (tumour, node, metastasis) classifica-
tion and presence of viruses. The observed differences
were considered statistically significant at p <0.05.
Results
The prevalence of HPV and EBV was higher in patients
than in controls (p < 0.001). HPV DNA was detected in
30.8 % of patients, EBV DNA in 51.3 %, while in control
group in 2.5 % and 20.0 %, respectively. Epidemiological,
clinical and virological characteristics of patients are
shown in Table 2. The level of all tested cytokines and
growth factors was higher in patients than in controls
both in serum and in saliva. The concentration of these
biomarkers in the patients group was higher in saliva
than in serum (Table 3). The level of IL-10 was statisti-
cally higher in smoking patients, in patients infected
with EBV, HPV as well as in EBV-HPV co-infection
(Table 4).
There was a relationship between the concentration of
both TNF-α and VEGF and the histological grade of the
tumour (G) and the size of tumour (T stage), while TGF-β
level was related to N stage. The level of the TNF-α was
higher in patients infected with EBV, whereas TGF-β was
higher in HPV and HPV/EBV co-infected patients. IL-10
concentration was higher in HPV, EBV as well as in
HPV/EBV co-infected patients.
Discussion
Various cytokines and growth factors play a significant
role both in inflammation and carcinogenesis. Some
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cytokines are considered as pro-inflammatory (TNF-α,
IFN-ɣ), whereas other are associated with anti-inflamma-
tory effects (TGF-β) [2]. To the best of our know-
ledge, IL-10, TGF-β1, TNF-α and VEGF levels in
patients infected with HPV and/or EBV have not
been studied in the Polish population with oropha-
ryngeal cancer.
Interleukin-10 (cytokine synthesis inhibitor factor, CSIF)
is an important cytokine produced by several cells such as
normal and neoplastic B cells, macrophages, T cells and
some cancer cells [19, 20]. The immunosuppressive effects
of IL-10 in the tumour environment have been repeatedly
confirmed [21]. Our study demonstrated higher levels of
IL-10 in saliva and serum samples of patients with OSCC
Table 2 Epidemiological, clinical and virological characteristics of patients (%)
EBV P value HPV P value
Positive N = 40 Negative N = 38 Positive N = 24 Negative N = 54
Sex female 2.5 15.8 0.0401* 4.2 11.1 0.2908
male 97.5 84.2 95.8 88.9
Age 40–49 20.0 10.5 0.4902 0 22.2 0.5692
50–69 40.0 47.4 75.0 29.6
70 + 40.0 42.1 25.0 48.2
Place of residence urban 70.0 57.9 0.2652 75.0 59.3 0.1736
rural 30.0 42.1 25.0 40.7
Smoking yes 80.0 78.9 0.9083 83.3 77.8 0.5692
no 20.0 21.1 16.7 22.2
Alcohol yes 45.0 42.1 0.7966 33.3 48.2 0.2196
no 55.0 57.9 66.7 57.8
Histological grading G 1 20.0 31.6 0.4911 33.3 22.8 0.0023*
2 75.0 63.2 55.0 77.8
3 5.0 5.2 16.7 0
T stage 1 10.0 15.8 0.0908 0 18.5 0.0004*
2 45.0 42.1 75.0 29.7
3 30.0 10.5 8.3 25.9
4 15.0 31.6 16.7 25.9
N stage N0 50.0 63.2 0.7043 58.3 55.6 0.7948
N1 20.0 15.8 16.7 18.5
N2 15.0 10.5 16.7 11.1
N3 15.0 10.5 8.3 14.8
*statistically significant
Table 3 Serum and salivary level of cytokines in patients and
controls
Patients Controls P value
Serum
IL-10 (pg/ml) 2.3 (1.2–3.9) 1.65 (0.54–2.9) 0.0003a
TGF-β (ng/ml) 11.3 (3.5–164.1) 7.8 (1.8–26.2) 0.0005a
VEGF (pg/ml 614 (14–1374) 210 (17–712) 0.0004a
TNF-α (ng/ml) 15.9 (4.9–39.1) 12.9 (10.4–19.5) 0.1397
Saliva
IL-10 (pg/ml) 5.9 (2.9–12.7) 2.5 (0.45–5.1) 0.00002a
TGF-β (ng/ml) 24.1 (7–87.9) 14.8 (5.4–30.1) 0.00002a
VEGF (pg/ml) 4321 (1566–7791) 280 (130–980) 0.0000a
TNF-α (ng/ml) 23.1 (15.8–26.0) 11.3 (8.2–17.7) 0.00002a
median, test U Manna Whitney’a
astatistically significant
Table 4 Association of cytokines and growth factors levels with
clinicopathological features
IL-10 TNF-α VEGF TGF-β
Smoking 0.0017* 0.1542 0.4652 0.9853
Alcohol 0.1325 0.0915 0.1433 0.3278
Histological grade G 0.1105 0.0344* 0.0421* 0.7569
T stage 0.8636 0.0412* 0.0005* 0.2400
N stage 0.2592 0.3230 0.2878 0.0062*
EBV 0.0002* 0.0456* 0.0502 0.2842
HPV 0.0382* 0.7348 0.9016 0.0396*
HPV + EBV 0.0331* 0.6416 0.1180 0.0117*
*Statistically significant
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than in control subjects. Moreover, IL-10 concentration in
saliva was higher than in serum. Goncalves et al. [22]
detected high expression of IL-10 in the tumour samples
and elevated levels of this cytokine in saliva of patients
with OSCC, which enabled to distinguish patients with
cancer from healthy individuals. Jiang et al. [23] addition-
ally studied correlation between IL-10 and advancing
cancer lesions on animal models. In their research higher
concentrations of IL-10 were associated with more severe
disease and poorer prognosis of cancer. Lathers [24]
observed an increase in the level of IL-10 with the forma-
tion of metastases in the lymph nodes. The influence of
IL-10 on more severe cancer disease is explained by antag-
onistic effect of IL-10 on the formation of pro-
inflammatory cytokines (IL-6, TNF, IL-1α, IL-1β, IL-12)
and inhibition of the inflammatory response, which plays
an important role in the development of cancer.
Tumour necrosis factor α (TNF-α) is a cytokine in-
volved in systemic inflammation and is one of the
cytokines that make up the acute phase reaction. TNF-α
is secreted by macrophages, monocytes, neutrophils,
T-cells, NK-cells following their stimulation by bacter-
ial lipopolysaccharides [25]. It has a wide spectrum of
biological activities including antitumour and antiviral
activity. TNF-α may be involved in carcinogenesis through
induction of proliferation, invasion, and metastasis be-
cause it may have both tumour-necrotic and tumour-
promoting activities [26]. In our study a significantly
higher level of this cytokine was obtained in the patients’
saliva comparing with the control group. In subjects with
OSCC, TNF-α levels were higher in saliva than in serum.
It may indicate the activity of the protein in close proxim-
ity to the tumour. Krishnan et al. [27] obtained signifi-
cantly higher levels of TNF-α both in saliva and in the
blood of the patients with OSCC. In a study carried out by
Juretic et al. [28] salivary concentration of TNF-α was
higher both in patients with premalignant oral lesions and
in patients with OSCC as compared with healthy individ-
uals. Rhodus [29], on the basis of his research analyzing the
concentration of TNF-α in saliva, suggests that this cyto-
kine can be used as a prognostic parameter for cancer.
TGF-β is a cytokine involved in various biological
processes. The TGF-β pathway regulates many of the
cellular processes and alterations in the signalling cascade
may promote tumour development. The anti-proliferative
activity of TGF-β1 is essential for maintaining normal
tissue homeostasis and this activity of TGF-β1 is lost in
many types of tumours [30, 31]. Some researchers point to
an increase of TGF-β concentration in the case of tumour
growth and they emphasize the prognostic features of
this protein [32]. Other studies show no difference
between the concentration of TGF-β in tissue samples
and saliva [23]. These differences may come from the
multiple effects of this cytokine on immune cells, the
formation of blood vessels and fluctuation depending
on the stage of cancer. Our study demonstrated sig-
nificantly higher levels of TGF-β both in saliva and in
serum of patients with OSCC. Moreover, salivary level
was higher than serum concentration of this cytokine
in the group of patients.
Because angiogenesis is essential for the growth and
metastasis of tumours, we also investigated serum and
salivary levels of VEGF (Vascular Endothelial Growth
Factor), which is the main regulator of this process. In
vitro experiments showed that VEGF stimulates mitosis
of endothelial cells and their migration. VEGF may be
also secreted by tumour cells and it acts in an autocrine
manner to promote cell growth [33, 34]. In our study
VEGF levels were significantly higher in patients with
OSCC than in healthy controls both in serum and saliva.
Similar results were obtained by other researchers [34–36],
but there are also studies which demonstrated elevated
salivary and serum levels of VEGF in OSCC patients wi-
thout finding significant differences [37, 38]. Congruent
outcomes were obtained by researchers who assessed the
level of VEGF in tissue samples [39]. In a study carried out
by Upile et al. [34] a direct correlation between T stage and
N stage of the patients with OSCC and VEGF levels were
found. Our research revealed a significant correlation be-
tween VEGF salivary and serum levels and clinicopathologi-
cal features such as histology grading and T stage. These
relationships are so important that some researchers sug-
gest the possibility of using this protein as a tumour marker
[35, 36].
As it is well documented, the main risk factors for
head and neck cancer are tobacco, alcohol abuse and
betel quid chewing but some types of head and neck
SCC are linked to viral infections such as HPV and EBV.
HPV infection has been recognized as a necessary but
not the only one cause of certain types of human can-
cers because cancer eventually develops only in a small
group of individuals infected with HPV. Other factors
are, therefore, necessary for malignant transformation of
HPV-infected cells [21, 40]. Chronic inflammation by
HPV with an inadequate host immune response may
provide a potential for tumor formation. According to
Chuang et al. [41], the development of HPV(+) OSCC is
associated with IL-10 expression. These researchers
demonstrated that HPV(+) patients with OSCC had
higher IL-10 mRNA levels than HPV(−) patients. They
also suggested that IL-10 may suppress T-cell immunity,
which results in a persistent HPV infection. The correl-
ation between higher levels of IL-10 in the group of
patients with OSCC and the presence of HPV was also
observed in our study. Moreover, the increase in the
expression of IL-10 gene in people infected with HPV
was demonstrated in the case of other types of tumours,
such as cervical cancer [42].
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VEGF is also a cytokine investigated toward its prog-
nostic value in patients infected with HPV. Jo et al. [43]
observed a significant increase in VEGF mRNA levels in
HPV(+) tumours. Other researchers [44], however, did
not obtain similar results. The present study also did not
reveal such a correlation between VEGF and HPV status.
Many researchers found that HPV(+) and HPV(−)
OSCC are two distinct forms of the disease. In general,
HPV(+) cancer patients are younger, have a much better
prognosis than HPV(−) [39, 41, 43, 45]. According to
Chen et al. [45], high expression of IL-10 predicts a poor
prognosis in OSCC. Chuang et al. [41] based on their
research indicated that IL-10 mRNA expression levels
may independently predict the survival and recurrence
rates in patients with HPV(+) OSCC, but not in those
with HPV(−) cancer.
Shi et al. [46] suggest that two DNA viruses, Epstein-
Barr virus (EBV) and human papillomavirus (HPV), are
associated with 38 % of all virus-associated cancers and
the probability of one patient infected with two distinct
types of viruses is increasing. During primary infection
EBV infects oral epithelial cells and B lymphocytes. Like
other herpesviruses, EBV has a productive lytic cycle
and a latent form. Latently infected B cells can occasion-
ally be stimulated to reactivate EBV [47]. Activation of
the lytic phase or reactivation from latency is a key to
virus transmission. Most diseases related to EBV infec-
tion are associated with the latent form of infection.
Some of early products that further act as transactivators
of the viral lytic phase are BZLF1 and BRLF1. BZLF1
plays important role in attenuating the host immune
response to lytic viral infection [48]. In the lytic infection
BZLF1 inhibits the activity of the promoter for the gene
encoding TNF-α receptor and decreased expression of
the TNFR1 protein [49]. Besides, it is unable to induce
cellular apoptosis. TNF-α activates expression of various
important inflammatory genes and it induces apoptosis.
BZLF1 stimulates expression of both TGF-β and IL-10
[49]. Epstein-Barr virus late gene BCRF1 is very similar to
the human IL-10 gene (84 % homology in amino acids se-
quence). This late viral gene product vIl-10 (BCLF1) plays
an important role for the protection of the virus from the
host immune response. The results of this process, namely
the infection with EBV, may develop tumour diseases.
Many questions are unclear and will need to be an-
swered by future studies. All the above-mentioned cyto-
kines and growth factors act on the tumour growth.
Some of them were definitely studied and explained long
ago, some are constantly being investigated. Explaining
the reasons for this influence is very difficult because
many cytokines interact in various ways on cells, often
in an antagonistic manner, depending on the concentra-
tion. There is no doubt that viruses which have the
ability to connect with the genetic material of the host
cells can significantly disrupt gene expression for cyto-
kines and growth factors.
It has been confirmed in numerous studies that HPV and
EBV have the ability to cause various cancers, but there is a
lack of studies which determine variability in the levels of
cytokines in patients with OSCC with EBV infections.
Conclusions
Our results clearly indicate increased levels of IL-10, TNF-
α, TGF-β and VEGF both in serum and saliva and they
suggest that these cytokines may constitute valuable tools
in diagnosis, treatment and prognosis in cancer disease.
However, further research is still required to prove the
role and mode of action of potential biomarkers.
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